Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

venous thromboembolism

- PMLiVE

Boehringer files Pradaxa for new VTE indication in Europe

Seeks to add to anticoagulant’s approvals

- PMLiVE

J&J acquires oncology candidate in $1bn Aragon buy

ARN-509 is in phase II development for castration resistant prostate cancer

- PMLiVE

Eylea set to challenge Lucentis in UK after NICE recommendation

Bayer’s medicine recommended for NHS use to treat wet AMD

- PMLiVE

Bayer wins EU approval for Xarelto in ACS

Comes despite US FDA decision not to recommend extra indication for anticoagulant

- PMLiVE

J&J expects to file 10 new pharma products by 2017

Healthcare company also expects 25 significant brand-line extensions

- PMLiVE

New chief information officer at Bayer Healthcare

Promotion for Johannes Schubmehl

- PMLiVE

France ignores EMA and suspends Bayer’s Diane 35

National Agency for the Safety of Drugs and Health Products contradicts PRAC verdict

Bayer symbol

EMA says Bayer’s Diane 35 should remain on European market

Agency investigation concludes acne treatment's benefits outweigh its risks

- PMLiVE

J&J’s Simponi wins FDA approval in ulcerative colitis

Adds to rheumatoid arthritis, psoriatic arthritis and active ankylosing spondylitis indications in the US

Bayer symbol

Bayer boosts consumer care business with Steigerwald purchase

Fuels ambition to become world leader in OTC medicines

Bayer symbol

FDA clears Bayer/ Algeta’s prostate cancer radiotherapy

Approval for Xofigo comes three months ahead of schedule

- PMLiVE

FDA says Janssen’s myeloma drug is a ‘breakthrough therapy’

Should speed up regulatory process for daratumumab

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links